Mustang Bio Inc (MBIO) concluded trading on Thursday at a closing price of $0.21, with 308.62 million shares of worth about $64.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.06% during that period and on Thursday the price saw a gain of about 18.02%. Currently the company’s common shares owned by public are about 49.61M shares, out of which, 45.93M shares are available for trading.
Stock saw a price change of 25.01% in past 5 days and over the past one month there was a price change of 10.53%. Year-to-date (YTD), MBIO shares are showing a performance of 18.02% which decreased to -84.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Mustang Bio Inc shares is 1.91 million. The stock is currently trading 13.81% above its 20-day simple moving average (SMA20), while that difference is down -4.80% for SMA50 and it goes to -38.30% lower than SMA200.
Mustang Bio Inc (NASDAQ: MBIO) currently have 49.61M outstanding shares and institutions hold larger chunk of about 5.72% of that.
The stock has a current market capitalization of $10.36M and its 3Y-monthly beta is at 1.77. It has posted earnings per share of -$1.79 in the same period. It has Quick Ratio of 0.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MBIO, volatility over the week remained 38.30% while standing at 16.70% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on May 18, 2021 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by B. Riley FBR stated Mustang Bio Inc (MBIO) stock as a Buy in their note to investors on October 02, 2020, suggesting a price target of $9 for the stock. On November 20, 2019, Cantor Fitzgerald Initiated their recommendations, while on August 13, 2019, H.C. Wainwright Initiated their ratings for the stock with a price target of $7. Stock get an Overweight rating from Cantor Fitzgerald on June 21, 2019.
